2015
DOI: 10.1590/0102-311xca010315
|View full text |Cite
|
Sign up to set email alerts
|

Relação Nacional de Medicamentos: uma construção permanente

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4

Citation Types

0
3
0
2

Year Published

2017
2017
2023
2023

Publication Types

Select...
4
1

Relationship

2
3

Authors

Journals

citations
Cited by 5 publications
(5 citation statements)
references
References 3 publications
0
3
0
2
Order By: Relevance
“…Como um instrumento norteador a RENAME facilita as ações de planejamento, aquisição de medicamentos e de organização da Assistência Farmacêutica no âmbito do SUS, sendo assim, as equipes de saúde, principalmente os profissionais que possuem a autonomia da prescrição, devem seguir a RENAME e o Formulário Terapêutico Nacional, para poder realizar a escolha adequada da melhor terapêutica a cada paciente (SANTANA; CATANHEIDE, 2015).…”
Section: Introductionunclassified
“…Como um instrumento norteador a RENAME facilita as ações de planejamento, aquisição de medicamentos e de organização da Assistência Farmacêutica no âmbito do SUS, sendo assim, as equipes de saúde, principalmente os profissionais que possuem a autonomia da prescrição, devem seguir a RENAME e o Formulário Terapêutico Nacional, para poder realizar a escolha adequada da melhor terapêutica a cada paciente (SANTANA; CATANHEIDE, 2015).…”
Section: Introductionunclassified
“…Some authors argue that these and other regulatory measures adopted by the government have helped to promote harmonization between "lists of recommendations" and "funding lists" by institutionalizing the assessment of efficacy, safety and cost-effectiveness and defining funding responsibilities 3 , while others claim that the loose application of the essential medicines concept in the definition proposed by the Rename is a step backward and recommend that priorities should be set with due regard to Brazil's disease burden and health concerns 4 . Another challenge in relation to the regulation and adoption of health technologies is guaranteeing the analysis, registration and availability of products that are of little interest to the pharmaceutical industry or those used for diseases that have few treatment options, such as medicines for rare diseases or illnesses that typically affect vulnerable groups [5][6][7] .…”
Section: Introductionmentioning
confidence: 99%
“…Potential inappropriate medications (PIMs) are drugs with a high-risk of provoking more side effects than benefits, even though there are available alternatives that can be substituted 5 . In Brazil, PIMs are still being prescribed and used as top-notch treatments for the majority of elderly patients, although there is evidence of negative results 6,7 .…”
Section: Introductionmentioning
confidence: 99%
“…In Brazil, PIMs are still being prescribed and used as top-notch treatments for the majority of elderly patients, although there is evidence of negative results 6,7 . This occurs because these medications are in the Brazilian National Essential Medicines List (RENAME) and are distributed free of charge by the Brazilian public health system (SUS) 5 .…”
Section: Introductionmentioning
confidence: 99%